PARTICIPATE IN A CLINICAL RESEARCH STUDY
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Chronic kidney disease
GKPTN
A Prospective International Multi-Centre, Observational Cohort Study of Incident and Prevalent Patients Diagnosed with a Kidney Disease
(562) 385-7463
Nina Patel, MD
The George Clinical Institute for Global Health, Australia
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Chronic kidney disease
ZENITH
A Phase 2b Multicentre, Randomised, Double-Blind, Placebo- Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with an eGFF Between 20 and 60 mL/min/1.73 m2
(562) 385-7463
Nina Patel, MD
AstraZeneca
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Chronic kidney disease-related hyperkalemia and metabolic acidosis
NEUTRALIZE
A Double-blind Randomized Placebo-controlled Parallel Design Multicenter Phase IIIb Study of the Effect of Sodium Zirconium Cyclosilicate (SZC) on Serum Potassium and Serum Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease
(562) 385-7020
Nina Patel, MD
AstraZeneca
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Diabetic foot ulcers
NuShield
A Phase 3, Prospective, Multicenter, Randomized, Controlled Clinical Study of NuShield® and Standard of Care (SOC) Compared to SOC Alone for the Management of Diabetic Foot Ulcers
(562) 385-6201
David Armstrong, DPM
Organogenesis, Inc.
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Epilepsy
Illuminate
A Phase 4, Long-Term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated with Epidiolex (Cannabidiol) Oral Solution
(562) 385-7020
Hui Gong, MD
GW Research LTD
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Epilepsy
RAISE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IV Ganaxolone in RSE Patients Who Have Failed Benzodiazepines and Two or More Second Line Intravenous Antiepileptic Drugs (AEDs)
(562) 385-7020
Susan Shaw, MD
Marinus Pharmacetuticals
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Polycystic kidney disease
FALCON
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease
(562) 385-7048
Nina Patel, MD
Reata Pharmaceuticals
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Spinal cord injury-related urinary bladder dysfunction and incontinenece
Bladder Stim
The Effectiveness of Early Sacral Nerve Stimulation in Improving Bladder- Related Complications and Quality of Life after Acute Traumatic Spinal Cord Injury
(562) 385-6201
David Ginsberg, MD
University of Utah
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Stroke rehabilitation
FitMi Plus
FitMi Plus: Smart Functional Modules for Practicing Activities of Daily Living after Stroke
(562) 385-7463
Susan Shaw, MD
Flint Rehab
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Stroke- or TBI-related lower extremity spasticity
ABOLISH
A Phase 4 International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the effectiveness of ABOBONT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort
(562) 385-7048
Ziyad Ayyoub, MD
Ipsen
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Stroke- or TBI-related lower extremity spasticity
PHLEX-LOW
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of a Single-Dose of MYOBLOC in Adult Subjects with Lower Limb Monoplegia or Hemiplegia Spasticity Due to Stroke or TBI, Followed by an Open-Label Extension Safety Study of Multiple Doses
(562) 385-7048
Ziyad Ayyoub, MD
Supernus Pharmaceuticals
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Stroke- or TBI-related upper extremity spasticity
DIRECTION
A Phase 4 Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity
(562) 385-7048
Ziyad Ayyoub, MD
Ipsen
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Stroke- or TBI-related upper extremity spasticity
PHLEX-UP
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Followed by an Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC®
(562) 385-7048
Ziyad Ayyoub, MD
Supernus Pharmaceuticals
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Ulcers of the lower extremity
AnGes
A Phase 2 Double-Blind, Randomized, Placebo-Bontrolled Study to Assess the Efficacy and Safety of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower Extremity
(562) 385-6201
David Armstrong, DPM
AnGes USA, Inc.
Indication:
Trial Name:
Description:
Contact:
Investigator:
Sponsor:
Users of long-term indwelling catheters
Silq
A Phase 4, Prospective, Multi-center, Randomized Study to Assess the Ability of the Silq ClearTract Urinary Catherter to Reduce Biofilm Formation When Compared to Two Types of Commercially Available Foley Catheters (Silver-Coated Latex and Silicone-Coated Latex)
(562) 385-6201
Evgeniy Kreydin, MD
Silq Technologies Corporation